Advisors Asset Management Inc. Lowers Stake in Solventum Corporation $SOLV

Advisors Asset Management Inc. lessened its position in Solventum Corporation (NYSE:SOLV) by 72.2% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 6,290 shares of the company’s stock after selling 16,351 shares during the period. Advisors Asset Management Inc.’s holdings in Solventum were worth $477,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Strengthening Families & Communities LLC raised its holdings in Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after acquiring an additional 260 shares during the last quarter. Barrett & Company Inc. grew its position in shares of Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after purchasing an additional 268 shares during the period. IMG Wealth Management Inc. acquired a new position in Solventum in the second quarter valued at $31,000. Smartleaf Asset Management LLC lifted its position in Solventum by 193.4% during the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after buying an additional 352 shares during the period. Finally, MTM Investment Management LLC purchased a new position in Solventum during the second quarter worth about $40,000.

Solventum Stock Performance

NYSE:SOLV opened at $85.61 on Wednesday. The firm has a 50-day moving average of $74.25 and a two-hundred day moving average of $73.83. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14. The stock has a market cap of $14.85 billion, a P/E ratio of 9.86, a PEG ratio of 9.03 and a beta of 0.26. Solventum Corporation has a 1-year low of $60.70 and a 1-year high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.07. The business had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The company’s revenue for the quarter was up .7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.64 earnings per share. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum declared that its board has approved a stock buyback plan on Thursday, November 20th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a research note on Thursday, October 30th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a research report on Monday. Wells Fargo & Company increased their price target on shares of Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Monday, September 15th. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Finally, UBS Group restated a “neutral” rating on shares of Solventum in a report on Friday, November 21st. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $87.00.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.